9 completed, 2 recruiting, 1 not yet recruiting, 1 terminated. 6 Phase 1, 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 6 | Completed 3, Recruiting 2, Terminated 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow delpazolid: new trials by email Literature Review of delpazolid trials Research Report on delpazolid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis MDR-END Plus regimen, Standard-of-care (SoC) treatment - Rifampicin-Resistant Tuberculosis | Phase 3 | Not yet recruiting | Seoul National University Hospital | 294 | 2026-10-01 | 2026-06-30 |
| Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex Delpazolid - Nontuberculous Mycobacterium Infection, Mycobacterium Abscessus Infection | Phase 2 | Completed | LigaChem Biosciences, Inc. | 24 | 2024-01-16 | 2026-07-10 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| PanACEA - STEP2C -01 BTZ-043, Rifampicin, Isoniazid - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | Phase 2 | Recruiting | Michael Hoelscher | 390 | 2023-04-14 | 2025-10-07 |
| A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia Delpazolid, Vancomycin, Placebo of Delpazolid - MRSA Bacteremia | Phase 2 | Terminated | LigaChem Biosciences, Inc. | 40 | 2022-04-26 | 2025-05-06 |
| PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) Delpazolid, Bedaquiline, Delamanid, Moxifloxacin - Infections and Infestations, Pulmonary Tuberculosis | Phase 2 | Completed | LigaChem Biosciences, Inc. | 76 | 2021-10-28 | 2025-09-16 |
| Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R), LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) - Healthy | Phase 1 | Completed | LigaChem Biosciences, Inc. | 25 | 2021-01-14 | 2021-06-25 |
| A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK LCB01-0371 800mg, QD, LCB01-0371 400mg, BID, LCB01-0371 800mg, BID - Pulmonary Tuberculosis | Phase 2 | Completed | LigaChem Biosciences, Inc. | 79 | 2016-12-10 | 2020-02-06 |
| IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers LCB01-0371, LCB01-0371 400mg - Healthy | Phase 1 | Completed | LigaChem Biosciences, Inc. | 24 | 2016-09-01 | 2018-04-10 |
| To Evaluate the Effect of Food on Pharmacokinetics(PK), Phase I Clinical Study of LCB01-0371 LCB01-0371 Tablet 800 mg(R), LCB01-0371 Tablet 800 mg(T) - Healthy | Phase 1 | Completed | LigaChem Biosciences, Inc. | 30 | 2015-09-01 | 2016-03-23 |
| Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371 LCB01-0371 800mg, LCB01-0371 800mg BID, LCB01-0371 1200mg BID - Healthy | Phase 1 | Completed | LigaChem Biosciences, Inc. | 30 | 2014-06-01 | 2015-09-04 |
| Multiple Ascending Dose Study for LCB01-0371 LCB01-0371 800mg, LCB01-0371 1200mg, Placebo - Healthy | Phase 1 | Completed | LigaChem Biosciences, Inc. | 30 | 2013-03-01 | 2014-11-17 |
| A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study LCB01-0371, Linezolid - Healthy | Phase 1 | Completed | LigaChem Biosciences, Inc. | 70 | 2012-03-01 | 2014-11-17 |
Tuberculosis, Pulmonary (4) · Bacteremia (1) · Infections (1) · Mycobacterium Infections, Nontuberculous (1) · Sepsis (1) · Tuberculosis (1) · Tuberculosis, Multidrug-Resistant (1)
LigaChem Biosciences, Inc. (10) · Michael Hoelscher (1) · Seoul National University Hospital (1) · University College, London (1)
South Korea (9) · South Africa (4) · Tanzania (3) · Uganda (2) · Gabon (1) · Malawi (1) · Moldova (1) · Mozambique (1) · Vietnam (1)
Hongbin Kim (1) · Jae-Joon Yim, MD, PhD (1) · Jae-Yong Chung (1) · Jaeyong Chung, M.D., Ph.D (1) · Jennifer Hughes, MBBCh (1) · Jeongha Mok, MD, PhD (1) · Kyun-Seop Bae, M.D., Ph. D. (1) · Kyun-Seop Bae, MD, PhD. (1) · Michael Hoelscher, Prof Dr. (1) · T.S Sim, M.D., Ph.D (1) · Young Lag Cho, Ph.D. (1)
PMID 29069400, PMID 29712654, PMID 30420289, PMID 30559004, PMID 34871098, PMID 37280643, PMID 38436463, PMID 39801777, PMID 40645198, PMID 41705840